Adam Crystal oversees clinical and development operations as the President of Research and Development at Tango Therapeutics. Previously, Adam served as Chief Medical Officer of C4 Therapeutics where he oversaw the advancement of several targeted protein degraders into clinical trials in oncology patients. Prior to that, he was at Novartis Institutes for Biomedical Research, most recently as Senior Director, where he led several early clinical development programs. Adam has also served as a medical oncologist at Massachusetts General Hospital where he researched resistance mechanisms to targeted therapies.

After completing his Bachelor of Arts in neuroscience at the University of Pennsylvania, Adam earned his MD and PhD in neuroscience from the University of Pennsylvania School of Medicine. He completed his internal medicine training at Massachusetts General Hospital and his fellowship in medical oncology at the Massachusetts General Hospital Cancer Center and the Dana-Farber Cancer Institute.